Estrogen receptor-mediated enhancement of venous relaxation in female rat: Implications in sex-related differences in varicose veins

Journal of Vascular Surgery

Volumn 51, Issue 4, 2010, Pages 972-981

  Raffetto, Joseph D ^a,b,c   Qiao, Xiaoying ^a   Beauregard, Katie G ^a   Khalil, Raouf A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHLORIDE; CALCIUM ION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; N(G) NITROARGININE METHYL ESTER; PHENYLEPHRINE; POTASSIUM CHLORIDE;

ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXTRACELLULAR SPACE; FEMALE; INFERIOR CAVA VEIN; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; VARICOSIS; VASCULAR ENDOTHELIUM; VEIN DILATATION; VENOCONSTRICTION;

ACETYLCHOLINE; ANGIOTENSIN II; ANIMALS; CALCIUM SIGNALING; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITRILES; PHENOLS; PHENYLEPHRINE; POTASSIUM CHLORIDE; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, ANGIOTENSIN; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SEX FACTORS; VARICOSE VEINS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS; VENA CAVA, INFERIOR;

EID: 77949891639     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.11.074     Document Type: Article

References (53)

1. Raffetto J.D., and Khalil R.A. Mechanisms of varicose vein formation: valve dysfunction and wall dilation. Phlebology 23 (2008) 85-98
2. Beebe-Dimmer J.L., Pfeifer J.R., Engle J.S., and Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol 15 (2005) 175-184
3. Robertson L., Evans C., and Fowkes F.G. Epidemiology of chronic venous disease. Phlebology 23 (2008) 103-111
4. Sisto T., Reunanen A., Laurikka J., Impivaara O., Heliövaara M., Knekt P., et al. Prevalence and risk factors of varicose veins in lower extremities: Mini-Finland Health Survey. Eur J Surg 161 (1995) 405-414
5. Bergan J.J., Schmid-Schönbein G.W., Smith P.D., Nicolaides A.N., Boisseau M.R., and Eklof B. Chronic venous disease. N Engl J Med 355 (2006) 488-498
6. White J.V., and Ryjewski C. Chronic venous insufficiency. Perspect Vasc Surg Endovasc Ther 17 (2005) 319-327
7. Brand F.N., Dannenberg A.L., Abbott R.D., and Kannel W.B. The epidemiology of varicose veins: the Framingham Study. Am J Prev Med 4 (1988) 96-101
8. Criqui M.H., Jamosmos M., Fronek A., Denenberg J.O., Langer R.D., Bergan J., et al. Chronic venous disease in an ethnically diverse population: the San Diego Population Study. Am J Epidemiol 158 (2003) 448-456
9. Fowkes F.G., Lee A.J., Evans C.J., Allan P.L., Bradbury A.W., and Ruckley C.V. Lifestyle risk factors for lower limb venous reflux in the general population: Edinburgh Vein Study. Int J Epidemiol 30 (2001) 846-852
10. Criqui M.H., Denenberg J.O., Bergan J., Langer R.D., and Fronek A. Risk factors for chronic venous disease: the San Diego Population Study. J Vasc Surg 46 (2007) 331-337
11. Kroeger K., Ose C., Rudofsky G., Roesener J., and Hirche H. Risk factors for varicose veins. Int Angiol 23 (2004) 29-34
12. Jukkola T.M., Mäkivaara L.A., Luukkaala T., Hakama M., and Laurikka J. The effects of parity, oral contraceptive use and hormone replacement therapy on the incidence of varicose veins. J Obstet Gynaecol 26 (2006) 448-451
13. Miller V.M., Barber D.A., Fenton A.M., Wang X., and Sieck G.C. Gender differences in response to endothelin-1 in coronary arteries: transcription, receptors and calcium regulation. Clin Exp Pharmacol Physiol 23 (1996) 256-259
14. Barber D.A., and Miller V.M. Gender differences in endothelium-dependent relaxations do not involve NO in porcine coronary arteries. Am J Physiol Heart Circ Physiol 273 (1997) H2325-H2332
15. Rubanyi G.M., Freay A.D., Kauser K., Sukovich D., Burton G., Lubahn D.B., et al. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender difference and effect of estrogen receptor gene disruption. J Clin Invest 99 (1997) 2429-2437
16. 2+ entry mechanisms of vasoconstriction in Wistar-Kyoto and spontaneously hypertensive rats. Hypertension 34 (1999) 931-936
17. i in vascular smooth muscle cells of female rat. Am J Physiol Cell Physiol 278 (2000) C834-C844
18. Tostes R.C., David F.L., Carvalho M.H., Nigro D., Scivoletto R., and Fortes Z.B. Gender differences in vascular reactivity to endothelin-1 in deoxycorticosterone-salt hypertensive rats. J Cardiovasc Pharmacol 36 5 suppl 1 (2000) S99-S101
19. Varbiro S., Matrai M., Szekeres M., Nadasy G.L., Szaky E., Mericli M., et al. Intramural coronary artery constrictor reactivity to thromboxane is higher in male than in female rats. Gynecol Endocrinol 22 (2006) 44-47
20. Matsumoto T., Kakami M., Kobayashi T., and Kamata K. Gender differences in vascular reactivity to endothelin-1 (1-31) in mesenteric arteries from diabetic mice. Peptides 29 (2008) 1338-1346
21. Li Z., Krause D.N., Doolen S., and Duckles S.P. Ovariectomy eliminates sex differences in rat tail artery response to adrenergic nerve stimulation. Am J Physiol Heart Circ Physiol 272 (1997) H1819-H1825
22. Geary G.G., Krause D.N., and Duckles S.P. Estrogen reduces myogenic tone through a nitric oxide-dependent mechanism in rat cerebral arteries. Am J Physiol Heart Circ Physiol 275 (1998) H292-H300
23. 2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol 19 (1999) 1034-1040
24. Orshal J.M., and Khalil R.A. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol 286 (2004) R233-R249
25. Serock M.R., Wells A.K., and Khalil R.A. Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov 3 (2008) 165-186
26. Kanashiro C.A., and Khalil R.A. Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am J Physiol Cell Physiol 280 (2001) C34-C45
27. Mendelsohn M.E. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 90 (2002) 3F-6F
28. Mendelsohn M.E., and Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science 308 (2005) 1583-1587
29. Smiley D.A., and Khalil R.A. Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels. Curr Med Chem 16 (2009) 1863-1887
30. Chambliss K.L., Yuhanna I.S., Mineo C., Liu P., German Z., Sherman T.S., et al. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ Res 87 (2000) E44-E52
31. Pare G., Krust A., Karas R.H., Dupont S., Aronovitz M., Chambon P., et al. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90 (2002) 1087-1092
32. Zhu Y., Bian Z., Lu P., Karas R.H., Bao L., Cox D., et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 295 (2002) 505-508
33. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., and Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307 (2005) 1625-1630
34. Filardo E., Quinn J., Pang Y., Graeber C., Shaw S., Dong J., et al. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 148 (2007) 3236-3245
35. Haas E., Meyer M.R., Schurr U., Bhattacharya I., Minotti R., Nguyen H.H., et al. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 49 (2007) 1358-1363
36. Prossnitz E.R., Oprea T.I., Sklar L.A., and Arterburn J.B. The ins and outs of GPR30: a transmembrane estrogen receptor. J Steroid Biochem Mol Biol 109 (2008) 350-353
37. 2+-dependent contraction in inferior vena cava of female rat. Am J Physiol Regul Integr Comp Physiol (2009) [E-pub before print: doi:10.1152/ajpregu.00465.2009]
38. Raffetto J.D., Qiao X., Koledova V.V., and Khalil R.A. Prolonged increases in vein wall tension increase matrix metalloproteinases and decrease constriction in rat vena cava: Potential implications in varicose veins. J Vasc Surg 48 (2008) 447-456
39. + channels: relevance to varicose vein formation. J Vasc Surg 45 (2007) 373-380
40. Sun J., Meyers M.J., Fink B.E., Rajendran R., Katzenellenbogen J.A., and Katzenellenbogen B.S. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology 140 (1999) 800-804
41. Stauffer S.R., Coletta C.J., Tedesco R., Nishiguchi G., Carlson K., Sun J., et al. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 43 (2000) 4934-4947
42. Harrington W.R., Sheng S., Barnett D.H., Petz L.N., Katzenellenbogen J.A., and Katzenellenbogen B.S. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol 206 (2003) 13-22
43. Filardo E.J., Quinn J.A., Bland K.I., and Frackelton Jr. A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14 (2000) 1649-1660
44. Kleuser B., Malek D., Gust R., Pertz H.H., and Potteck H. 17-Beta-estradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30. Mol Pharmacol 74 (2008) 1533-1543
45. Schiffrin E.L., and Touyz R.M. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade. J Am Coll Cardiol 42 (2003) 911-913
46. i during inhibition of coronary smooth muscle contraction by 17β-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther 291 (1999) 44-52
47. e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. Role of RGD peptides. J Surg Res (2009) [E-pub before print: doi:10.1016/j.jss.2008.09.022]
48. Giardina J.B., Green G.M., Cockrell K.L., Granger J.P., and Khalil R.A. TNF-alpha enhances contraction and inhibits endothelial NO-cGMP relaxation in systemic vessels of pregnant rats. Am J Physiol Regul Integr Comp Physiol 283 (2002) R130-R143
49. Payne J.A., Alexander B.T., and Khalil R.A. Decreased endothelium-dependent NO-cGMP vascular relaxation and hypertension in growth-restricted rats on a high-salt diet. Hypertension 43 (2004) 420-427
50. Mashiah A., Berman V., Thole H.H., Rose S.S., Pasik S., Schwarz H., et al. Estrogen and progesterone receptors in normal and varicose saphenous veins. Cardiovasc Surg 7 (1999) 327-331
51. Knaapen M.W., Somers P., Bortier H., De Meyer G.R., and Kockx M.M. Smooth muscle cell hypertrophy in varicose veins is associated with expression of estrogen receptor-beta. J Vasc Res 42 (2005) 8-12
52. Félétou M., and Vanhoutte P.M. EDHF: new therapeutic targets?. Pharmacol Res 49 (2004) 565-580
53. Perrot-Applanat M., Cohen-Solal K., Milgrom E., and Finet M. Progesterone receptor expression in human saphenous veins. Circulation 92 (1995) 2975-2983